| Alias |
quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;Cabozantinib;Cabozantinib malate (XL184);(2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1);1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,(2S)-2-hydroxybutanedioic acid;Cabozantinib L-Malate Salt;Cabozantinib S-malate;XL-184 L(-)-Malic acid salt;Cabozantinib malate;Cabozantinib malate salt;cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxyquinoline-4-yloxy)phenyl]amide (4-fluoro-phenyl)amide (L)-malate salt;cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide L-malate;N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-d;Smalate;UNII-DR7ST46X58;XL184;XL-184;AC-27471;C32H30FN3O10;N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide mono-(2S)-malate;XL-184 malate;s4001;HFCFMRYTXDINDK-WNQIDUERSA-N;cabozantinib (S)-malate;Cabozantinib s-malate [USAN];MLS006010951;CABOZANTINIB S-MALATE [ORANGE BOOK];Cometriq (TN);CHEMBL2103868;CHEBI:72319;1140909-48-3 (malate);Cabozantinib S-malate?;N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2S)-2-hydroxybutanedioate;Q27139901;1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-N-(4-fluorophenyl)-mono((2S)-2-hydroxybutanedioate);Cabozantinib (S-malate);MFCD20923480;(2S)-2-hydroxybutanedioic acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;D10095;EX-A2819;BMS907351;Cabometyx (TN);N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2S)-2-hydroxybutanedioate;SW218093-2;DTXSID60915949;CABOZANTINIB S-MALATE [WHO-DD];HY-12044;cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (S) malate salt;N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate;XL184 (S-malate);BMS-907351 (S-malate);1140909-48-3;N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate;Cabometyx;SMR004702755;cabozantinib L-malate;AS-75255;Cabozantinib s-malate (USAN);Cabozantinib malate (JAN);1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)- mono((2S)-2-hydroxybutanedioate);CABOZANTINIB MALATE [JAN];Cometriq;N-(4-((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE MONO((2S)-2-HYDROXYBUTANEDIOATE);AKOS025401945;CCG-270301;CCG-270301;1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedi... |
